The PROMISe to increase precision in adjuvant therapy for early breast cancer: To &#8220;Type&#8221; or to &#8220;Print&#8221;? by F. Cardoso & G. Curigliano
EDITORIAL OPEN
The PROMISe to increase precision in adjuvant therapy for
early breast cancer: To “Type” or to “Print”?
npj Breast Cancer  (2018) 4:12 ; doi:10.1038/s41523-
018-0064-8
The PROMIS trial (Prospective Study of MammaPrint in Breast
Cancer Patients With an Intermediate Recurrence Score) enrolled
840 patients with early-stage breast cancer and an intermediate
21-gene assay (21-GA) recurrence score of 18 to 30. The primary
aim of the trial was to assess the change in physician treatment
decision before vs. after receiving the MammaPrint (also called 70-
Gene Signature (70-GS)) result.1 Among the 840 patients who
underwent 70-GS classiﬁcation, 374 (44.5%) had a low-risk and 466
(55.5%) had a high-risk result. A signiﬁcant change in adjuvant
treatment was associated with receiving the 70-GS classiﬁcation
with an OR of 0.64 (95%CI, 0.50–0.82; McNemar test, P < .001) for
all patients. Among the low-risk patients, 108 of 374 (28.9%) had
chemotherapy removed from their treatment recommendation;
and among the high-risk patients, 171 of 466 (36.7%) had
chemotherapy added, for an overall change in treatment decision
in 282 (33.6%) of patients. The authors concluded that the 70-GS
provides clinically actionable information regarding patients
classiﬁed as intermediate risk by the 21-GA and that clinicians
may consider ordering the 70-GS for patients with an intermediate
recurrence score for adjuvant therapy decisions.
Several genomic signatures exist and have been tested with a
higher or lower level of evidence. The only two such tests that
have undergone a prospective randomized phase 3 validation trial
are MammaPrint and Oncotype, from which only the former has
presented the complete primary analysis results. All these
genomic tests are clinically useful mainly in luminal breast cancer
subtype since, for the time being, both triple negative and HER-2-
positive subtypes mandate the use of adjuvant chemotherapy. In
addition, their clinical utility and cost-effectiveness are higher
when used solely in cases where doubts remain regarding the
beneﬁt of adjuvant chemotherapy after evaluating all traditional
clinico-pathological criteria. But how to choose between available
tests? Should we “Type” or “Print” “genomic equivocal” estrogen
receptor (ER) positive cases?
The MINDACT trial results clearly demonstrate the heterogene-
ity within ER positive HER2-negative cancers.2 In the high clinical/
low genomic risk population who did not receive adjuvant
chemotherapy (1550 patients, 48% node positive) a 94.7% 5-year
DMFS (Distant-Metastasis-Free-Survival) was observed, conﬁrming
the primary hypothesis (of at least 92%) and proving that the
integration of the 70-GS permits the identiﬁcation of a cohort of
ER-positive tumors with good prognosis with endocrine therapy
alone, regardless of larger T stage and N1 status. A secondary
analysis of the trial compared the outcome of high clinical/low
genomic risk patients when receiving or not chemotherapy. Albeit
not sufﬁciently powered to fully answer this randomized question,
MINDACT has shown a small beneﬁt of about 1.5% in 5-years
DMFS for those who did receive chemotherapy. This difference
must be put into perspective with the known short and especially
long-term side effects of adjuvant chemotherapy (about 0.5%
severe cardiac insufﬁciency and 0.5% acute leukemia). The
MINDACT results allow us to put a number on the other side of
the scale, helping the patient to take the ﬁnal decision. Through
the years, some criticisms were raised regarding the design of the
MINDACT trial and consequently the interpretation of its results.
The design of a trial depends on many factors: scientiﬁc, logistic,
ﬁnancial and ethical. An upfront and blinded randomization
between traditional clinico-pathological factors and genomic
test would have been both ethically and logistically unfeasible;
one cannot hide from patients and their treating oncologists
the pathology results. Furthermore, the clinical use of the
test was always foreseen to be in conjunction with and not in
place of the traditional clinico-pathological risk factors. Having as
primary endpoint a direct comparison between chemotherapy vs.
not exclusively in the relevant group of high clinical/low
genomic risk patients would have required a far too high sample
size, which would have made the trial ﬁnancially and logistically
impossible to run. The chosen design3 was a compromise and
extensively discussed for over two years before the start of the
trial. The very high rate of compliance in all treatment cohorts
shows that both physicians and patients embraced the ﬁnal
design decision. Over a decade has passed since both MINDACT
and TailorX were designed and recruited patients, and the
overall understanding of the added value of genomic tests has
improved. There is now consensus that they are best used in
combination with traditional factors reﬂecting tumor burden i.e.,
tumor size and lymph node status. In fact, some genomic tests
(such as Prosigna, Endopredict) are reported as a combined score
of both genomic and pathology factors. A still controversial issue
is the fact that the same tumor in the same patient may have a
different risk assessment depending on the test used. Moreover,
since risk is a continuous variable, one may argue that the
genomic risk score should also be reported as a continuous
variable. The deﬁnition of the high/intermediate/low cut-offs is a
highly debatable issue, depending on the individual views about
risk and beneﬁt. An issue with the oncotype recurrence score that
may be considered by some as problematic is the deﬁnition of
three risk groups and the fact that, until we have the results of
TailorX trial, it is unknown which treatment decision should be
taken for the intermediate risk group,. MammaPrint provides a
more straightforward result with only two risk groups (high/low),
with a well-deﬁned cut-off that has remained the same since the
development of the test and is now the only genomic test with a
level 1A evidence for its clinical utility regarding chemotherapy
decision-making.
Adding to the points discussed above, the PROMIS trial
deﬁnitely suggests to “Print” instead of “Type”. The 70-GS
reclassiﬁed the 840 intermediate patients as low risk in 374 cases
(44.5%) and high risk in 466 cases (55.5%). These high-risk and
low-risk patients were found at every RS in the intermediate range.
When analyzing the subgroup of 368 patients for whom the
original physician-selected treatment recommendation (based on
the intermediate 21-GA) conﬂicted with that indicated by the 70-
GS, 279 (75.8%) of these patients had their treatment regimen
changed; 108 of 142 70-GS low-risk patients who originally were
recommended to receive chemotherapy had chemotherapy
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removed from their treatment recommendation, and 171 of 226
70-GS high-risk patients who originally were not recommended to
receive CT had CT added to their treatment recommendation after
the 70-GS result. Overall, 339 of 374 low-risk patients (90.6%) were
recommended no adjuvant chemotherapy, and 409 of 466 high
risk patients (87.8%) were recommended adjuvant chemotherapy.
The change in treatment decision was the same regardless of LN
status; 251 of 744 patients with LN-negative disease (33.7%) and
27 of 84 patients with LN-positive disease (32.1%) had a change
to their chemotherapy treatment decision. After receiving the
70-GS result, physicians were queried in every case as to how the
result inﬂuenced their conﬁdence level regarding the chosen
treatment plan: to “Type” or to “Print”? Physicians reported greater
conﬁdence in their treatment recommendations in 660 cases
(78.6%) and reduced conﬁdence in 49 cases (5.8%). The PROMIS
trial has some pitfalls such as the lack of recurrence and survival
data that were not collected, and inclusion criteria limited to
patients with ER-positive/HER2-negative disease and the pub-
lished intermediate-range RS of 18 to 30, not the TailorX
intermediate RS of 11 to 25.
From all available data, we strongly support to “Print” instead of
to “Type”, provided that the traditional clinico-pathological factors
are also “imprinted”. From the balance between tumor biology
and tumor burden, some questions remain unanswered and
should be further studied such as stage 3 breast cancers with
favorable pathology and low genomic signatures/scores, for
whom (neo)adjuvant chemotherapy may be unnecessary.
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